Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors

I. Klomp; S. U. Dalm; P. M. van Koetsveld; F. Dogan-Oruc; M. de Jong; L. J. Hofland

doi:10.1007/s00259-020-04988-4

Abstract

Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.

Original language	English
Article number	OP-830
Pages (from-to)	S411-S412
Number of pages	2
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	47
Issue number	Suppl 1
DOIs	https://doi.org/10.1007/s00259-020-04988-4
Publication status	Published - Sept 2020
Event	33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) - Duration: 22 Oct 2020 → 30 Oct 2020

Access to Document

10.1007/s00259-020-04988-4

https://link.springer.com/article/10.1007/s00259-020-04988-4

Cite this

Klomp, I., Dalm, S. U., van Koetsveld, P. M., Dogan-Oruc, F., de Jong, M., & Hofland, L. J. (2020). Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 47(Suppl 1), S411-S412. Article OP-830. https://doi.org/10.1007/s00259-020-04988-4

@article{e6819d67fd0e480aa4731e84a66ea75d,

title = "Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors",

abstract = "Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.",

author = "I. Klomp and Dalm, \{S. U.\} and \{van Koetsveld\}, \{P. M.\} and F. Dogan-Oruc and \{de Jong\}, M. and Hofland, \{L. J.\}",

year = "2020",

month = sep,

doi = "10.1007/s00259-020-04988-4",

language = "English",

volume = "47",

pages = "S411--S412",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

number = "Suppl 1",

note = "33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) ; Conference date: 22-10-2020 Through 30-10-2020",

}

Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors. / Klomp, I.; Dalm, S. U.; van Koetsveld, P. M. et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, No. Suppl 1, OP-830, 09.2020, p. S411-S412.

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

TY - JOUR

T1 - Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors

AU - Klomp, I.

AU - Dalm, S. U.

AU - van Koetsveld, P. M.

AU - Dogan-Oruc, F.

AU - de Jong, M.

AU - Hofland, L. J.

PY - 2020/9

Y1 - 2020/9

N2 - Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.

AB - Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000577424101028&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1007/s00259-020-04988-4

DO - 10.1007/s00259-020-04988-4

M3 - Meeting Abstract

SN - 1619-7070

VL - 47

SP - S411-S412

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - Suppl 1

M1 - OP-830

T2 - 33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)

Y2 - 22 October 2020 through 30 October 2020

ER -

Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this